-
Smart investors look beyond the obvious. The construction industry may be the hidden ...
-
Billions of dollars in brand name drugs are set to lose patent protection, and Barr ...
-
The Razr handset is getting old. The Krzr, Pebl and Slvr have failed to impress. ...
-
Rising copper prices have been a boon for Freeport McMoran Copper & Gold. We examine ...
-
The chip maker is cutting costs and introducing new products to turn its fortunes ...
-
EMC's 85.9% ownership of hotshot VMWare caused speculation that EMC was undervalued, ...
-
Three new companies are getting a chance to make chips for Nokia phones. Will this ...
-
Disputes with with Broadcom and Nokia are heating up. Investors beware, high litigation ...
-
Sales of Macintosh computers boosted Apple's fiscal third quarter results well beyond ...
-
Will this company soar with any customers other than teens and tweens?
-
The memory sector is wavering. Lam Research could falter right along with it, despite ...
-
With legal issues and pressure from generic drug manufacturers, drug company Biovail's ...
-
As Apple's iPhone release approaches, lofty expectations have raised the stock price. ...
-
Communications company Harris Corporation isn't a household name, but it has fingers ...
-
With its successful product pipeline, Gilead shines among biotechs, and its future ...
-
Escalating demand for ag products means Bunge should be thriving, but its free cash ...
-
Apple is gearing up for the release of its iPhone in June. This could actually be ...
-
Railroad stocks are losing popularity. Is FreightCar America worth your consideration?
-
While companies scramble to find alternative energy sources, McDermott is working ...
-
There's new talent at K-Swiss, and the shoe company might now be worth a second look.
-
Accenture appears to be leading the way when it comes to outsourcing and consulting ...
-
A look at the possible growing pains for the generic-drug manufacturing giant after ...